Pipeline Remepy’s hybrid Parkinson’s therapy poised for phase 3 PharmaphorumRemepy's Hybridopa therapy for Parkinson's, which combines an app with levodopa therapy, has shown efficacy in a phase 2 pilot study.NeuroscienceRead full story pharminent May 20, 2026 (Last updated: May 21, 2026) Pharmaphorum Remepy’s Hybridopa therapy for Parkinson’s, which combines an app with levodopa therapy, has shown efficacy in a phase 2 pilot study. Neuroscience Read full story Post navigation Previous: Immunovant’s potential autoimmune ‘blockbuster’; Wave’s RNA editing updateNext: ATS 2026: Long-term data show durable benefit of Trikafta for cystic fibrosis Related Stories Pipeline Chasing Dupixent, a biotech aims to make better antibody drugs for eczema pharminent August 11, 2026 Pipeline Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease pharminent August 11, 2026 Pipeline BioMarin axes asset from $270M Inozyme takeover, ending run in rare metabolic indication pharminent August 10, 2026
